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Sir,
The evaluation made by Arkenau et al (2008) on the impact
of progression free and overall survival of 29 phase I trials
performed on 212 consecutive patients is noteworthy. However, it
is necessary to emphasise that 54 (25%) of these patients
are affected by prostate cancer and 37 (68%) of them were not
pretreated with chemotherapy. The fact that patients with
such urological cancers have had a significant better outcome
compared with those with non-urological cancers, P¼0.001,
as reported by the authors, can be justified by the fact
that, after phase I trials, these patients not pretreated with
chemotherapy were probably treated with Docetaxel regimens,
which are known to be efficacious forms of therapy in hormone-
resistant prostate cancer. It would be very interesting to compare
the outcome of these two groups of patients with prostate cancer,
that is, those not pretreated vs those pretreated with chemo-
therapy. In case of no differences in the outcome, it could
be stated that patients whose prognosis is poor, despite
chemotherapy, could be safely given phase I chemotherapy trials
upfront without having been pretreated with any chemotherapy
regimen, with obvious advantages for the assessment of new
therapeutic drugs.
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